These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 34496081)

  • 61. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 24-Hour Levodopa-Carbidopa Intestinal Gel: Clinical Experience and Practical Recommendations.
    Thakkar S; Fung VSC; Merola A; Rollins M; Soileau MJ; Kovács N
    CNS Drugs; 2021 Feb; 35(2):137-149. PubMed ID: 33582982
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.
    Kestenbaum M; Fahn S
    Expert Opin Drug Saf; 2015 May; 14(5):761-7. PubMed ID: 25697185
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs.
    Ramot Y; Nyska A; Maronpot RR; Shaltiel-Karyo R; Tsarfati Y; Manno RA; Sacco G; Yacoby-Zeevi O
    Toxicol Pathol; 2017 Aug; 45(6):764-773. PubMed ID: 28891435
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.
    Tetrud J; Nausieda P; Kreitzman D; Liang GS; Nieves A; Duker AP; Hauser RA; Farbman ES; Ellenbogen A; Hsu A; Kell S; Khanna S; Rubens R; Gupta S
    J Neurol Sci; 2017 Feb; 373():116-123. PubMed ID: 28131167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.
    van Laar T; Nyholm D; Nyman R
    Acta Neurol Scand; 2016 Mar; 133(3):208-15. PubMed ID: 26213103
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
    Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
    Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
    Antonini A; Abbruzzese G; Berardelli A; Modugno N; Stroppa I; Tamma F; Sensi M; Mancini F; Cossu G; Stefani A; Tambasco N; Tessitore A; Fabbrini G; Pontieri FE; Solla P; Bentivoglio AR; Comi C; Minafra B; Riboldazzi G; Melchionda D; Martino T; Lopiano L
    J Neural Transm (Vienna); 2020 Jun; 127(6):881-891. PubMed ID: 32212015
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Subclinical affective and cognitive fluctuations in Parkinson's disease: a randomized double-blind double-dummy study of Oral vs. Intrajejunal Levodopa.
    Kulisevsky J; Bejr-Kasem H; Martinez-Horta S; Horta-Barba A; Pascual-Sedano B; Campolongo A; Marín-Lahoz J; Aracil-Bolaños I; Pérez-Pérez J; Izquierdo-Barrionuevo C; de Fàbregues O; Puente V; Crespo-Cuevas A; Calopa M; Pagonabarraga J
    J Neurol; 2020 Nov; 267(11):3400-3410. PubMed ID: 32607644
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features.
    Catalán MJ; Escribano PM; Alonso-Frech F
    Mov Disord; 2017 Apr; 32(4):624-625. PubMed ID: 28116835
    [No Abstract]   [Full Text] [Related]  

  • 72. Novel Levodopa Formulations for Parkinson's Disease.
    Freitas ME; Ruiz-Lopez M; Fox SH
    CNS Drugs; 2016 Nov; 30(11):1079-1095. PubMed ID: 27743318
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Levodopa-Carbidopa-Related Rash in Parkinson's Disease: A Case Series.
    Anang JBM
    Can J Neurol Sci; 2018 Sep; 45(5):588-589. PubMed ID: 30033887
    [No Abstract]   [Full Text] [Related]  

  • 74. Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.
    Müller T; Jugel C; Ehret R; Ebersbach G; Bengel G; Muhlack S; Klostermann F
    J Neural Transm (Vienna); 2011 Sep; 118(9):1329-33. PubMed ID: 21359971
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
    Chaudhuri KR; Pickard AS; Alobaidi A; Jalundhwala YJ; Kandukuri PL; Bao Y; Sus J; Jones G; Ridley C; Oddsdottir J; Najle-Rahim S; Madin-Warburton M; Xu W; Schrag A
    Pharmacoeconomics; 2022 May; 40(5):559-574. PubMed ID: 35307793
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
    Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
    Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients.
    Klostermann F; Bojarski C; Marzinzik F; Maier A; Schindlbeck KA; Ehlen F
    Mov Disord; 2017 Feb; 32(2):300-301. PubMed ID: 27859611
    [No Abstract]   [Full Text] [Related]  

  • 79. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
    LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
    Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.